BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-1.98%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.46B
AUM Growth
+$4.46B
(-14%)
Cap. Flow
-$467M
Cap. Flow
% of AUM
-10.47%
Top 10 Holdings %
Top 10 Hldgs %
48.58%
Holding
170
New
10
Increased
26
Reduced
81
Closed
22
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$50.6M |
| 2 |
AbbVie
ABBV
|
$18.9M |
| 3 |
Stryker
SYK
|
$17.3M |
| 4 |
Beam Therapeutics
BEAM
|
$17.1M |
| 5 |
Baxter International
BAX
|
$15.6M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$204M |
| 2 |
Arvinas
ARVN
|
$45.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$36.1M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$32.2M |
| 5 |
Tandem Diabetes Care
TNDM
|
$28.2M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Technology | 0.01% |
| 3 | Communication Services | 0.01% |
| 4 | Consumer Discretionary | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
10x Genomics
TXG
$1.74B
| $2.02M | 0.05% | 230,997 -39,731 | -15% | -$347K |
|
102
Bristol-Myers Squibb
BMY
$96B
| $1.56M | 0.03% | 25,566 -12,547 | -33% | -$765K |
|
103
Doximity
DOCS
$12.7B
| $1.38M | 0.03% | 23,816 -4,095 | -15% | -$238K |
|
104
Summit Therapeutics
SMMT
$17.6B
| $1.31M | 0.03% | 67,685 -102,909 | -60% | -$1.99M |
|
105
Dr. Reddy's Laboratories
RDY
$11.8B
| $1.21M | 0.03% | 91,916 -5,984 | -6% | -$78.9K |
|
106
VanEck Gold Miners ETF
GDX
$19B
| $1.2M | 0.03% | 26,200 | – | – |
|
107
Recursion Pharmaceuticals
RXRX
$2.04B
| $1.03M | 0.02% | 195,052 -182,754 | -48% | -$967K |
|
108
Sanofi
SNY
$121B
| $887K | 0.02% | +16,000 | New | +$887K |
|
109
Protagonist Therapeutics
PTGX
$3.67B
| $852K | 0.02% | 17,622 -6,096 | -26% | -$295K |
|
110
Rhythm Pharmaceuticals
RYTM
$6.85B
| $824K | 0.02% | 15,550 -8,046 | -34% | -$426K |
|
|
BBNX
111
Beta Bionics, Inc. Common Stock
BBNX
$819M
| $818K | 0.02% | +66,825 | New | +$818K |
|
112
Certara
CERT
$1.74B
| $809K | 0.02% | 81,740 -10,389 | -11% | -$103K |
|
113
BioNTech
BNTX
$24B
| $725K | 0.02% | 7,964 -368 | -4% | -$33.5K |
|
114
Zai Lab
ZLAB
$3.68B
| $723K | 0.02% | 20,000 +7,000 | +54% | +$253K |
|
115
Arcutis Biotherapeutics
ARQT
$1.86B
| $558K | 0.01% | 35,700 -3,800 | -10% | -$59.4K |
|
116
Zoetis
ZTS
$69.3B
| $513K | 0.01% | 3,114 -6,665 | -68% | -$1.1M |
|
117
Krystal Biotech
KRYS
$4.27B
| $478K | 0.01% | 2,650 -2,397 | -47% | -$432K |
|
118
iShares Russell 2000 ETF
IWM
$67B
| $459K | 0.01% | +2,300 | New | +$459K |
|
119
NewAmsterdam Pharma
NAMS
$2.71B
| $446K | 0.01% | 21,800 -3,200 | -13% | -$65.5K |
|
120
Teva Pharmaceuticals
TEVA
$21.1B
| $445K | 0.01% | 28,930 -31,668 | -52% | -$487K |
|
121
Vaxcyte
PCVX
$4B
| $426K | 0.01% | 11,290 -748 | -6% | -$28.2K |
|
122
Travere Therapeutics
TVTX
$1.56B
| $414K | 0.01% | 23,100 | – | – |
|
123
Madrigal Pharmaceuticals
MDGL
$9.76B
| $364K | 0.01% | 1,100 | – | – |
|
124
BridgeBio Pharma
BBIO
$9.89B
| $360K | 0.01% | 10,400 | – | – |
|
125
Merus
MRUS
$4.98B
| $337K | 0.01% | 8,000 | – | – |
|